查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889428

微生物组疗法市场预测至2032年：按治疗方法类型、目标领域、技术、应用、最终用户和地区分類的全球分析

Microbiome Therapies Market Forecasts to 2032 - Global Analysis By Therapy Type, Target Area, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 预测，2025 年全球微生物组疗法市场价值将达到 32 亿美元，预计到 2032 年将达到 146 亿美元。

预计在预测期内，微生物组疗法将以24.2%的复合年增长率高速成长。微生物组疗法是治疗方法。这些疗法利用益生菌、基因改造细菌、微生物移植或标靶微生物代谢物来治疗与肠道菌丛失衡相关的疾病。其应用范围不断扩大，涵盖胃肠道疾病、代谢性疾病、免疫调节、肿瘤和神经发育障碍等领域。先进的分析技术能够精确调控微生物组的相互作用，从而发展出与传统药物相比副作用较少的个人化治疗策略。

根据 Strategic Revenue Insights 的一项消费者调查，人们对肠道健康的日益关注推动了微生物组疗法需求的每年 20% 的增长，其中 62% 的受访者优先考虑益生菌以增强免疫和代谢功能。

对个人化医疗的需求日益增长

推动成长的主要动力是对个人化医疗日益增长的需求。人工智慧和基因测序等先进技术正在协助开发针对个体独特微生物组成的客製化微生物组疗法。这种从通用治疗模式转变为个人化治疗的转变将显着提高癌症、代谢紊乱和自体免疫疾病等复杂疾病的治疗效果。对精准医疗的关注是市场发展的关键驱动力，有望改善患者预后，并刺激该领域的投资和创新。

复杂的监管核准流程

复杂且不断变化的全球监管标准给市场带来了巨大挑战。儘管美国FDA已为生物治疗产品（LBP）制定了明确的核准途径，但欧洲和亚太地区的监管机构仍在製定各自的指导方针。这种缺乏协调性的情况为製造商带来了不确定性，导致产品核可延迟和研发成本显着增加。对于在多个国际市场营运的公司而言，如何应对这种分散且往往不稳定的监管环境仍然是一项重大限制。

代谢疾病的新应用

代谢疾病领域的新兴应用前景广阔，蕴藏着巨大的成长机会。目前，研究正不断深入，探讨肠道菌丛对肥胖、第二型糖尿病和非酒精性脂肪肝等疾病的直接影响。诸如诺和诺德基金会的「微生物组健康倡议」等重大倡议，正大力投资开发能够调节肠道菌丛以改善心血管代谢健康的新型治疗方法。这种认识的加深，为超越传统胃肠道适应症的治疗方法研发开闢了广阔的新天地。

关于活微生物产品的安全问题

活性微生物产品的潜在安全隐忧构成重大威胁。与传统药物不同，活性微生物产品含有活菌，这给产品的稳定性、与患者独特微生物群的相互作用以及传播抗生素抗药性基因的风险等方面带来了独特的挑战。此外，免疫力缺乏的患者也存在理论上的感染风险。这些隐患需要严格的长期安全监测和复杂的生产控制，这可能会阻碍投资并使监管核准复杂化，从而限制其在市场上的广泛应用。

新冠疫情的影响：

疫情初期扰乱了临床试验、生产活动和供应链，延缓了多个微生物组候选产品的研发进程。然而，人们对免疫韧性和宿主-微生物相互作用日益增长的兴趣促使疫情后投资回升，研究加速推进。数位化临床监测的广泛应用也为试验活动的恢復提供了支持。消费者和临床机构对微生物健康意识的提高，增强了他们对微生物组解决方案的兴趣，最终推动该领域在后疫情时代实现了更快增长，儘管初期面临一些运营挑战。

预计在预测期内，生物製剂治疗产品（LBP）细分市场将占据最大的市场份额。

由于其广泛的治疗适应症、高额的临床投入以及微生物组调节益处的有力证据，生物治疗产品（LBP）领域预计将在预测期内占据最大的市场份额。 LBP 可针对从胃肠道疾病到免疫和代谢紊乱等多种病症，具有广泛的应用潜力。菌株设计、製剂稳定性以及精准给药技术的进步进一步巩固了其优势。生物技术公司和製药公司之间日益密切的合作也进一步强化了主导地位。

预计在预测期内，肠道微生物组细分市场将呈现最高的复合年增长率。

预计在预测期内，肠道微生物组领域将呈现最高的成长速度。大量研究显示肠道菌丛组成与全身免疫、代谢调节和神经系统健康密切相关，这为上述预测提供了强力支撑。强大的临床研发管线、先进的定序技术以及诊断整合的进步正在加速治疗方法的发展。随着个人化营养、代谢和免疫调节疗法的扩展，以肠道为中心的干预措施正蓬勃发展。其广泛的疾病适用性和快速的科学检验，使该领域成为微生物组治疗领域中成长最快的方向。

占比最大的地区：

由于生物技术投资不断增长、临床研究基础设施不断完善以及消化器官系统和代谢疾病的高发，亚太地区预计将在预测期内占据最大的市场份额。中国、日本、韩国和新加坡等国家对微生物组创新表现出强而有力的监管支持。消费者意识的提高、精准医疗倡议的扩展以及先进定序技术的出现，进一步推动了相关技术的应用。强大的生产能力和政府支持的研发项目巩固了亚太地区的市场主导地位。

预计年复合成长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于强劲的创业投资流入、先进的临床试验生态系统以及创新疗法快速的商业化途径。美国凭藉其前沿的微生物组研究、精准医疗的高普及率以及生物技术公司、学术机构和製药公司之间的积极合作，处于主导地位。对标靶治疗的需求不断增长、FDA的支持性倡议以及多组体学的日益融合将进一步推动成长，使北美成为成长最快的市场。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球微生物组疗法市场（依治疗方法类型划分）

  • 生物医学产品（LBPs）
  • 粪便微生物移植（FMT）
  • 人工微生物群落
  • 新一代益生菌
  • 益生元和后生元
  • 基于噬菌体的治疗方法

6. 全球微生物组疗法市场（依目标区域划分）

  • 肠道微生物组
  • 口腔微生物组
  • 皮肤微生物组
  • 阴道微生物组
  • 呼吸道微生物组
  • 神经和免疫微生物组

7. 全球微生物组疗法市场（依技术划分）

  • 基因组学和定序技术
  • 计算建模与人工智慧
  • 合成生物学平台
  • 精准微生物组编辑
  • 试管内微生物组培养
  • 基于体学的分析工具

8. 全球微生物组疗法市场（按应用划分）

  • 消化系统疾病
  • 代谢性疾病
  • 免疫学/自体免疫疾病
  • 皮肤病
  • 精神健康与神经退化性疾病
  • 感染疾病

9. 全球微生物组疗法市场（以最终用户划分）

  • 製药公司
  • 生技公司
  • 研究和临床试验机构
  • 医院和治疗中心
  • 合约研究组织和学术机构
  • 专业健康诊所

10. 全球微生物组疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • Vedanta Biosciences
  • Finch Therapeutics
  • Synthetic Biologics
  • 4D Pharma
  • BiomeBank
  • Evelo Biosciences
  • Enterome
  • Rebiotix（Ferring）
  • Takeda
  • Johnson &Johnson
  • Novartis
  • GSK
  • Pfizer
  • Roche
  • Merck &Co.
Product Code: SMRC32802

According to Stratistics MRC, the Global Microbiome Therapies Market is accounted for $3.2 billion in 2025 and is expected to reach $14.6 billion by 2032 growing at a CAGR of 24.2% during the forecast period. Microbiome Therapies are treatments designed to modify or restore the microbial ecosystems within the human body to improve health outcomes. These therapies utilize probiotics, engineered bacteria, microbiota transplants, or targeted microbial metabolites to address diseases linked to dysbiosis. They play an expanding role in gastrointestinal disorders, metabolic diseases, immune modulation, oncology, and neurodevelopmental conditions. Advanced analytics enable precision modulation of microbiome interactions, creating personalized therapeutic strategies with fewer side effects compared to conventional drugs.

According to a Strategic Revenue Insights consumer survey, rising awareness of gut health drives 20% annual increase in demand for microbiome therapies, with 62% of respondents prioritizing probiotics for immune and metabolic support.

Market Dynamics:

Driver:

Increasing demand for personalized medicine

Growth is primarily fueled by the increasing demand for personalized medicine. Advanced technologies like artificial intelligence and genomic sequencing are enabling the development of microbiome therapies tailored to an individual's unique microbial composition. This shift from a universal treatment model to a personalized approach significantly enhances therapeutic efficacy for complex conditions such as cancer, metabolic disorders, and autoimmune diseases. This focus on precision health is a key market driver, promising better patient outcomes and driving investment and innovation in the sector.

Restraint:

Complex regulatory pathways for approval

The market faces significant challenges from complex and evolving global regulatory standards. While the U.S. FDA has established a defined pathway for Live Biotherapeutic Products (LBPs), regulatory agencies in Europe and Asia-Pacific are still refining their own guidelines. This lack of harmonization creates uncertainty for manufacturers, leading to extended product approval timelines and significantly higher development costs. Navigating this fragmented and often unsettled regulatory landscape remains a major restraint for companies operating across different international markets.

Opportunity:

Emerging applications in metabolic disorders

Emerging applications in metabolic disorders represent a significant growth opportunity. There is increasing research into the gut microbiome's direct influence on conditions like obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Major initiatives, such as the Novo Nordisk Foundation's Microbiome Health Initiative, are investing heavily to develop novel therapies that modulate the gut microbiota to improve cardiometabolic health. This expanding understanding opens a vast new frontier for therapeutic development beyond traditional gastrointestinal indications.

Threat:

Safety concerns with live microbial products

A key threat involves potential safety concerns associated with live microbial products. Unlike traditional drugs, LBPs contain living organisms, raising unique challenges regarding their stability, interaction with a patient's native microbiome, and the risk of transmitting antibiotic resistance genes. There is also a theoretical risk of infections in immunocompromised patients. These concerns necessitate rigorous long-term safety monitoring and complex manufacturing controls, which can deter investment and complicate regulatory approval, potentially limiting widespread market adoption.

Covid-19 Impact:

The pandemic initially disrupted clinical trials, manufacturing activities, and supply chains, slowing development timelines for several microbiome candidates. However, rising interest in immune resilience and host-microbe interactions stimulated renewed investment and accelerated research post-pandemic. Increased adoption of digital clinical monitoring supported recovery of trial activity. Heightened awareness of microbial health strengthened consumer and clinical interest in microbiome solutions, ultimately positioning the sector for faster growth in the post-COVID landscape despite early operational setbacks.

The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period

The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, owing to their broad therapeutic applicability, high clinical investment, and strong evidence demonstrating microbiome modulation benefits. LBPs target diverse conditions ranging from gastrointestinal disorders to immunological and metabolic diseases, creating wide adoption potential. Advances in strain engineering, formulation stability, and precision dosing reinforce their dominance. Growing partnerships between biotech firms and pharmaceutical companies further solidify the segment's leadership position.

The gut microbiome segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gut microbiome segment is predicted to witness the highest growth rate, reinforced by extensive research linking gut microbial composition to systemic immunity, metabolic regulation, and neurological health. Strong clinical pipelines, enhanced sequencing technologies, and rising diagnostic integration accelerate therapeutic development. As personalized nutrition, metabolic therapies, and immunomodulatory treatments expand, gut-focused interventions gain momentum. Broad disease applicability and rapid scientific validation position this segment as the fastest-advancing domain within microbiome therapeutics.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, ascribed to increasing biotech investments, expanding clinical research infrastructure, and high prevalence of gastrointestinal and metabolic disorders. Countries such as China, Japan, South Korea, and Singapore exhibit strong regulatory support for microbiome innovation. Rising consumer awareness, growing precision-medicine initiatives, and the presence of advanced sequencing capabilities further accelerate adoption. Robust manufacturing capacity and government-backed R&D programs solidify APAC's dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with strong venture capital influx, advanced clinical trial ecosystems, and rapid commercialization pathways for innovative therapeutics. The U.S. leads with cutting-edge microbiome research, high adoption of precision medicine, and active collaborations between biotech firms, academic centers, and pharmaceutical companies. Growing demand for targeted therapies, supportive FDA initiatives, and expanding multi-omics integration further propel growth, positioning North America as the fastest-expanding market.

Key players in the market

Some of the key players in Microbiome Therapies Market include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, Finch Therapeutics, Synthetic Biologics, 4D Pharma, BiomeBank, Evelo Biosciences, Enterome, Rebiotix (Ferring), Takeda, Johnson & Johnson, Novartis, GSK, Pfizer, Roche and Merck & Co.

Key Developments:

In November 2025, Vedanta progressed Phase II trials of VE303 for recurrent C. difficile infection, leveraging defined bacterial consortia to deliver standardized microbiome therapeutics with improved safety and efficacy profiles.

In October 2025, Seres advanced commercialization of VOWST(TM), its FDA-approved microbiome therapeutic for recurrent C. difficile infection, expanding distribution partnerships and initiating new clinical trials for ulcerative colitis and oncology indications.

In September 2025, Ferring scaled production of REBYOTA(TM), the first FDA-approved fecal microbiota therapy, expanding access in North America and Europe while investing in next-generation microbiome-based therapeutics for gastrointestinal disorders.

Therapy Types Covered:

  • Live Biotherapeutic Products (LBPs)
  • Fecal Microbiota Transplantation (FMT)
  • Engineered Microbial Consortia
  • Next-Generation Probiotics
  • Prebiotics & Postbiotics
  • Phage-Based Therapies

Target Areas Covered:

  • Gut Microbiome
  • Oral Microbiome
  • Skin Microbiome
  • Vaginal Microbiome
  • Respiratory Microbiome
  • Neural & Immune Microbiome

Technologies Covered:

  • Genomics & Sequencing Technologies
  • Computational Modeling & AI
  • Synthetic Biology Platforms
  • Precision Microbiome Editing
  • In Vitro Microbiome Culturing
  • Omics-Based Profiling Tools

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Immune & Autoimmune Disorders
  • Skin Disorders
  • Mental Health & Neurodegeneration
  • Infectious Diseases

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research & Clinical Labs
  • Hospitals & Treatment Centers
  • CROs & Academic Institutions
  • Specialty Wellness Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microbiome Therapies Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Live Biotherapeutic Products (LBPs)
  • 5.3 Fecal Microbiota Transplantation (FMT)
  • 5.4 Engineered Microbial Consortia
  • 5.5 Next-Generation Probiotics
  • 5.6 Prebiotics & Postbiotics
  • 5.7 Phage-Based Therapies

6 Global Microbiome Therapies Market, By Target Area

  • 6.1 Introduction
  • 6.2 Gut Microbiome
  • 6.3 Oral Microbiome
  • 6.4 Skin Microbiome
  • 6.5 Vaginal Microbiome
  • 6.6 Respiratory Microbiome
  • 6.7 Neural & Immune Microbiome

7 Global Microbiome Therapies Market, By Technology

  • 7.1 Introduction
  • 7.2 Genomics & Sequencing Technologies
  • 7.3 Computational Modeling & AI
  • 7.4 Synthetic Biology Platforms
  • 7.5 Precision Microbiome Editing
  • 7.6 In Vitro Microbiome Culturing
  • 7.7 Omics-Based Profiling Tools

8 Global Microbiome Therapies Market, By Application

  • 8.1 Introduction
  • 8.2 Gastrointestinal Disorders
  • 8.3 Metabolic Diseases
  • 8.4 Immune & Autoimmune Disorders
  • 8.5 Skin Disorders
  • 8.6 Mental Health & Neurodegeneration
  • 8.7 Infectious Diseases

9 Global Microbiome Therapies Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biotechnology Firms
  • 9.4 Research & Clinical Labs
  • 9.5 Hospitals & Treatment Centers
  • 9.6 CROs & Academic Institutions
  • 9.7 Specialty Wellness Clinics

10 Global Microbiome Therapies Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Ferring Pharmaceuticals
  • 12.3 Vedanta Biosciences
  • 12.4 Finch Therapeutics
  • 12.5 Synthetic Biologics
  • 12.6 4D Pharma
  • 12.7 BiomeBank
  • 12.8 Evelo Biosciences
  • 12.9 Enterome
  • 12.10 Rebiotix (Ferring)
  • 12.11 Takeda
  • 12.12 Johnson & Johnson
  • 12.13 Novartis
  • 12.14 GSK
  • 12.15 Pfizer
  • 12.16 Roche
  • 12.17 Merck & Co.

List of Tables

  • Table 1 Global Microbiome Therapies Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Microbiome Therapies Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Microbiome Therapies Market Outlook, By Live Biotherapeutic Products (LBPs) (2024-2032) ($MN)
  • Table 4 Global Microbiome Therapies Market Outlook, By Fecal Microbiota Transplantation (FMT) (2024-2032) ($MN)
  • Table 5 Global Microbiome Therapies Market Outlook, By Engineered Microbial Consortia (2024-2032) ($MN)
  • Table 6 Global Microbiome Therapies Market Outlook, By Next-Generation Probiotics (2024-2032) ($MN)
  • Table 7 Global Microbiome Therapies Market Outlook, By Prebiotics & Postbiotics (2024-2032) ($MN)
  • Table 8 Global Microbiome Therapies Market Outlook, By Phage-Based Therapies (2024-2032) ($MN)
  • Table 9 Global Microbiome Therapies Market Outlook, By Target Area (2024-2032) ($MN)
  • Table 10 Global Microbiome Therapies Market Outlook, By Gut Microbiome (2024-2032) ($MN)
  • Table 11 Global Microbiome Therapies Market Outlook, By Oral Microbiome (2024-2032) ($MN)
  • Table 12 Global Microbiome Therapies Market Outlook, By Skin Microbiome (2024-2032) ($MN)
  • Table 13 Global Microbiome Therapies Market Outlook, By Vaginal Microbiome (2024-2032) ($MN)
  • Table 14 Global Microbiome Therapies Market Outlook, By Respiratory Microbiome (2024-2032) ($MN)
  • Table 15 Global Microbiome Therapies Market Outlook, By Neural & Immune Microbiome (2024-2032) ($MN)
  • Table 16 Global Microbiome Therapies Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Microbiome Therapies Market Outlook, By Genomics & Sequencing Technologies (2024-2032) ($MN)
  • Table 18 Global Microbiome Therapies Market Outlook, By Computational Modeling & AI (2024-2032) ($MN)
  • Table 19 Global Microbiome Therapies Market Outlook, By Synthetic Biology Platforms (2024-2032) ($MN)
  • Table 20 Global Microbiome Therapies Market Outlook, By Precision Microbiome Editing (2024-2032) ($MN)
  • Table 21 Global Microbiome Therapies Market Outlook, By In Vitro Microbiome Culturing (2024-2032) ($MN)
  • Table 22 Global Microbiome Therapies Market Outlook, By Omics-Based Profiling Tools (2024-2032) ($MN)
  • Table 23 Global Microbiome Therapies Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Microbiome Therapies Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 25 Global Microbiome Therapies Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 26 Global Microbiome Therapies Market Outlook, By Immune & Autoimmune Disorders (2024-2032) ($MN)
  • Table 27 Global Microbiome Therapies Market Outlook, By Skin Disorders (2024-2032) ($MN)
  • Table 28 Global Microbiome Therapies Market Outlook, By Mental Health & Neurodegeneration (2024-2032) ($MN)
  • Table 29 Global Microbiome Therapies Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 30 Global Microbiome Therapies Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Microbiome Therapies Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 32 Global Microbiome Therapies Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 33 Global Microbiome Therapies Market Outlook, By Research & Clinical Labs (2024-2032) ($MN)
  • Table 34 Global Microbiome Therapies Market Outlook, By Hospitals & Treatment Centers (2024-2032) ($MN)
  • Table 35 Global Microbiome Therapies Market Outlook, By CROs & Academic Institutions (2024-2032) ($MN)
  • Table 36 Global Microbiome Therapies Market Outlook, By Specialty Wellness Clinics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.